Increase of bcl-2 protein in neuronal dendritic processes of cerebral cortex and hippocampus by the antiparkinsonian drugs, talipexole and pramipexole.
Treatment of rats for 4 days with the antiparkinsonian drugs, talipexole and pramipexole, markedly increased Bcl-2 immunoreactivity in neuronal dendritic processes in both cerebral cortex and hippocampus, but treatment for 1 day with either of these drugs did not. Repeated administration of talipexole or pramipexole may have neuroprotective effect in neurodegenerative disorders.
Takata
K
K
Department of Neurobiology, Kyoto Pharmaceutical University, 607-8412, Kyoto, Japan.
Kitamura
Y
Y
Kakimura
J
J
Kohno
Y
Y
Taniguchi
T
T
D000818:Animals; D000978:Antiparkinson Agents / Q000008:administration & dosage*; D001381:Azepines / Q000008:administration & dosage; D052160:Benzothiazoles; D002462:Cell Membrane / Q000378:metabolism; D002540:Cerebral Cortex / Q000187:drug effects / Q000378:metabolism*; D003600:Cytosol / Q000378:metabolism; D003712:Dendrites / Q000378:metabolism*; D018491:Dopamine Agonists / Q000008:administration & dosage; D004334:Drug Administration Schedule; D006624:Hippocampus / Q000187:drug effects / Q000378:metabolism*; D015151:Immunoblotting; D007274:Injections, Intraperitoneal; D008297:Male; D000077487:Pramipexole; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D013844:Thiazoles / Q000008:administration & dosage
D000978:Antiparkinson Agents; D001381:Azepines; D052160:Benzothiazoles; D018491:Dopamine Agonists; D019253:Proto-Oncogene Proteins c-bcl-2; D013844:Thiazoles; C024763:talipexole; D000077487:Pramipexole